keyword
MENU ▼
Read by QxMD icon Read
search

Meningococcal vaccinations

keyword
https://www.readbyqxmd.com/read/28318769/impact-of-meningococcal-c-conjugate-vaccination-four-years-after-introduction-of-routine-childhood-immunization-in-brazil
#1
Ana Lucia Andrade, Ruth Minamisava, Lisia Moura Tomich, Ana Paula Lemos, Maria Cecilia Gorla, Maria Cristina de Cunto Brandileone, Carla Madga S Domingues, Camile de Moraes, Gabriela Policena, Ana Luiza Bierrenbach
BACKGROUND: Routine infant immunization with meningococcal C conjugate (MCC) vaccination started in Brazil in November 2010, scheduled at three and five months plus a booster at 12-15months of age. No catch-up was implemented. We assessed the impact of vaccination on meningococcal C disease (MenC) four years after vaccination start in the National Immunization Program. METHODS: We performed an ecological quasi-experimental design from 2008 to 2014 using a deterministic linkage between the National Notification and the National Reference Laboratory databases for meningitis...
March 15, 2017: Vaccine
https://www.readbyqxmd.com/read/28318767/immunogenicity-and-safety-of-concomitant-administration-of-meningococcal-serogroup-b-4cmenb-and-serogroup-c-menc-crm-vaccines-in-infants-a-phase-3b-randomized-controlled-trial
#2
Marco Aurelio P Safadi, Federico Martinon-Torres, Lily Yin Weckx, Edson Duarte Moreira, Eduardo Jorge da Fonseca Lima, Ilhem Mensi, Marco Calabresi, Daniela Toneatto
BACKGROUND: After implementation of routine infant MenC vaccination, MenB remains a serious cause of meningococcal disease, yet to be targeted by vaccination programs in several countries. This study (NCT01339923) investigated the immunogenicity and safety of MenC CRM-conjugated vaccine (MenC-CRM) concomitantly administered with MenB vaccine (4CMenB). METHODS: Infants (N=251) were randomised 1:1 to receive 4CMenB and MenC-CRM (Group 1) or MenC-CRM alone (Group 2) at 3 and 5months (M3, M5) and a booster at 12months of age (M12), and pneumococcal vaccine at M3, M5, M7, M12...
March 15, 2017: Vaccine
https://www.readbyqxmd.com/read/28314560/the-epidemiology-of-invasive-meningococcal-disease-in-eu-eea-countries-2004-2014
#3
Robert Whittaker, Joana Gomes Dias, Miriam Ramliden, Csaba Ködmön, Assimoula Economopoulou, Netta Beer, Lucia Pastore Celentano
BACKGROUND: Invasive meningococcal disease (IMD) is a major cause of bacterial meningitis and septicaemia although infection by some serogroups may be prevented through vaccination. We aimed to describe the epidemiology of IMD in EU/EEA countries during 2004-2014 to monitor serogroup- and age-specific trends, and compare country trends by the period of meningococcal C conjugate (MCC) vaccine introduction. METHODS: We analysed IMD surveillance data by age, gender, serogroup, country and outcome...
March 14, 2017: Vaccine
https://www.readbyqxmd.com/read/28290948/mortality-surveillance-for-infectious-diseases-in-the-u-s-department-of-defense-1998-2013
#4
Robert N Potter, Ladd A Tremaine, Joel C Gaydos
INTRODUCTION: The Mortality Surveillance Division (MSD) of the U.S. Armed Forces Medical Examiner System was established in 1998 to improve surveillance for all military deaths although emphasizing deaths from infectious diseases. Establishment of the MSD was part of the 1997 Department of Defense initiative to improve surveillance and response for emerging infectious diseases. Before 1998, mortality surveillance was limited to compiling information from death certificates, a system that provided limited useful information and lacked the timeliness needed to take meaningful action to address emerging infectious disease threats...
March 2017: Military Medicine
https://www.readbyqxmd.com/read/28279715/characteristics-and-changes-in-invasive-meningococcal-disease-epidemiology-in-france-2006-2015
#5
I Parent du Chatelet, A E Deghmane, D Antona, E Hong, L Fonteneau, M K Taha, D Lévy-Bruhl
OBJECTIVES: This work aimed to describe the epidemiology of invasive meningococcal disease (IMD) in France, 2006-2015, including group- and genotype-specific disease burden, incidence trends before and after introduction of meningococcal C conjugate vaccines (MCCV) in 2010, and factors influencing the case fatality rate. METHODS: Mandatory notification data on incidence and IMD case characteristics were used. Genotyping of invasive strains and whole genome sequencing were performed by the French National Reference Center...
March 7, 2017: Journal of Infection
https://www.readbyqxmd.com/read/28277801/the-immunogenicity-and-safety-of-a-hib-menac-vaccine-a-non-inferiority-randomized-observer-blind-trial-in-infants-aged-3-5-months
#6
Yu-Xiao Wang, Hong Tao, Jian-Li Hu, Jing-Xin Li, Wei-Ming Dai, Jin-Fang Sun, Pei Liu, Jie Tang, Wen-Yu Liu, Feng-Cai Zhu
BACKGROUND: The objective of this study was to evaluate the immunogenicity and safety of the novel combined Haemophilus influenzae type b-Neisseria meningitidis serogroup A and C-tetanus toxoid conjugate vaccine (Hib-MenAC). RESEARCH DESIGN AND METHODS: We conducted a non-inferiority, randomized, observer-blind, positive control clinical trial in 900 healthy infants aged between 3-5 months in Funing County, Jiangsu Province, China. Participants were randomly allocated, in a ratio of 2:1 (block=6), to receive experimental combined Hib-MenAC vaccines co-administrated with placebo or the co-administration of licensed Hib vaccine and MenAC vaccine, according to a three-dose immunization schedule...
March 9, 2017: Expert Review of Vaccines
https://www.readbyqxmd.com/read/28262331/adverse-events-following-quadrivalent-meningococcal-crm-conjugate-vaccine-menveo%C3%A2-reported-to-the-vaccine-adverse-event-reporting-system-vaers-2010-2015
#7
Tanya R Myers, Michael M McNeil, Carmen S Ng, Rongxia Li, Paige W Lewis, Maria V Cano
BACKGROUND: Limited data are available describing the post-licensure safety of meningococcal vaccines, including Menveo®. We reviewed reports of adverse events (AEs) to the Vaccine Adverse Event Reporting System (VAERS) to assess safety in all age groups. METHODS: VAERS is a national spontaneous vaccine safety surveillance system co-administered by the Centers for Disease Control and Prevention and the US Food and Drug Administration. We searched the VAERS database for US reports of adverse events in persons who received Menveo from 1 January 2010 through 31 December 2015...
March 2, 2017: Vaccine
https://www.readbyqxmd.com/read/28253232/erratum-vol-66-no-5
#8
(no author information available yet)
In the report "Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older - United States, 2017," on page 138, the fifth bullet point under the heading "Meningococcal vaccination" should have read "Young adults aged 16 through 23 years (preferred age range is 16 through 18 years) who are healthy and not at increased risk for serogroup B meningococcal disease may receive either a 2-dose series of MenB-4C at least 1 month apart or a 2-dose series of MenB-FHbp at 0 and 6 months for short-term protection against most strains of serogroup B meningococcal disease...
March 3, 2017: MMWR. Morbidity and Mortality Weekly Report
https://www.readbyqxmd.com/read/28249046/impact-of-vaccine-herd-protection-effects-in-cost-effectiveness-analyses-of-childhood-vaccinations-a-quantitative-comparative-analysis
#9
Marisa Holubar, Maria Christina Stavroulakis, Yvonne Maldonado, John P A Ioannidis, Despina Contopoulos-Ioannidis
BACKGROUND: Inclusion of vaccine herd-protection effects in cost-effectiveness analyses (CEAs) can impact the CEAs-conclusions. However, empirical epidemiologic data on the size of herd-protection effects from original studies are limited. METHODS: We performed a quantitative comparative analysis of the impact of herd-protection effects in CEAs for four childhood vaccinations (pneumococcal, meningococcal, rotavirus and influenza). We considered CEAs reporting incremental-cost-effectiveness-ratios (ICERs) (per quality-adjusted-life-years [QALY] gained; per life-years [LY] gained or per disability-adjusted-life-years [DALY] avoided), both with and without herd protection, while keeping all other model parameters stable...
2017: PloS One
https://www.readbyqxmd.com/read/28222677/molecular-characterization-of-invasive-capsule-null-neisseria-meningitidis-in-south-africa
#10
Karistha Ganesh, Mushal Allam, Nicole Wolter, Holly B Bratcher, Odile B Harrison, Jay Lucidarme, Ray Borrow, Linda de Gouveia, Susan Meiring, Monica Birkhead, Martin C J Maiden, Anne von Gottberg, Mignon du Plessis
BACKGROUND: The meningococcal capsule is an important virulence determinant. Unencapsulated meningococci lacking capsule biosynthesis genes and containing the capsule null locus (cnl) are predominantly non-pathogenic. Rare cases of invasive meningococcal disease caused by cnl isolates belonging to sequence types (ST) and clonal complexes (cc) ST-845 (cc845), ST-198 (cc198), ST-192 (cc192) and ST-53 (cc53) have been documented. The clinical significance of these isolates however remains unclear...
February 21, 2017: BMC Microbiology
https://www.readbyqxmd.com/read/28220707/first-description-of-a-rifampicin-resistant-neisseria-meningitidis-serogroup-y-strain-causing-recurrent-invasive-meningococcal-disease-in-hungary
#11
Ákos Tóth, Brigitta Berta, Tamás Tirczka, Csilla Jekkel, Anita Ábrahám, Zoltán Prohászka, Zsófia Bognár, Tímea Erdősi
A Hungarian soldier previously immunized against Neisseria meningitidis by quadrivalent polysaccharide vaccine was twice infected with meningococci within six weeks. The patient was treated with ceftriaxone during both episodes and he successfully recovered. His close contacts received rifampicin prophylaxis. An investigation was performed to characterize the genetic background of the pathogens to ascertain if the recurrent invasive meningococcal disease was caused by the same strain and to find out the reason for reinfection...
February 21, 2017: Acta Microbiologica et Immunologica Hungarica
https://www.readbyqxmd.com/read/28213046/splenectomy-as-a-destination-improving-quality-of-care-among-asplenic-veterans-through-a-travel-clinic
#12
Aaron P Mitchell, Joel C Boggan, Karen Lau, David L Simel
BACKGROUND: Asplenic patients are at risk for severe infections, but adherence to recommended preventive education and vaccination is poor. The goal of this study was to demonstrate that a targeted intervention can improve vaccination rates in a population of asplenic veterans. METHODS: Surgically asplenic patients actively receiving care in our health care system were identified via a database search. Patients were contacted via mailed letters and encouraged to attend an existing travel clinic with a new process designed for asplenic patients...
February 14, 2017: American Journal of Medicine
https://www.readbyqxmd.com/read/28196734/bactericidal-activity-of-sera-from-adolescents-vaccinated-with-bivalent-rlp2086-against-meningococcal-serogroup-b-outbreak-strains-from-france
#13
Muhamed-Kheir Taha, Julio Cesar Hawkins, Paul Liberator, Ala-Eddine Deghmane, Lubomira Andrew, Li Hao, Thomas R Jones, Lisa K McNeil, Robert E O'Neill, John L Perez, Kathrin U Jansen, Annaliesa S Anderson
OBJECTIVES: Bivalent rLP2086 (Trumenba®; MenB-FHbp), composed of two factor H binding proteins (FHbps), is a vaccine approved in the United States for prevention of Neisseria meningitidis serogroup B (MnB) invasive meningococcal disease (IMD). Bactericidal activity of sera from subjects vaccinated with bivalent rLP2086 was assessed against MnB isolates from recent disease outbreaks in France. METHODS: MnB isolates from IMD cases were characterized by whole genome sequencing and FHbp expression was assessed using a flow cytometry-based assay...
February 10, 2017: Vaccine
https://www.readbyqxmd.com/read/28194210/recommended-immunization-schedule-for-children-and-adolescents-immunization-guideline-8th-edition-released-by-the-korean-pediatric-society-in-2015
#14
REVIEW
Jong-Hyun Kim, Eun Hwa Choi, Su Eun Park, Yae-Jean Kim, Dae Sun Jo, Yun-Kyung Kim, Byung-Wook Eun, Jina Lee, Soo-Young Lee, Hyunju Lee, Ki Hwan Kim, Kyung-Hyo Kim
This report includes the recommended immunization schedule table for children and adolescents based on the 8th (2015) and revised 7th (2012) Immunization Guidelines released by the Committee on Infectious Diseases of the Korean Pediatric Society (KPS). Notable revised recommendations include: reorganization of the immunization table with a list of vaccines on the vertical axis and the corresponding age on the horizontal axis; reflecting the inclusion of Haemophilus influenzae type b vaccine, pneumococcal conjugate vaccine, and hepatitis A vaccine into the National Immunization Program since 2012; addition of general recommendations for 2 new Japanese encephalitis (JE) vaccines and their interchangeability with existing JE vaccines; addition of general recommendations for quadrivalent meningococcal conjugate vaccines and scope of the recommended targets for vaccination; and emphasizing catch-up immunization of Tdap vaccine...
December 2016: Korean Journal of Pediatrics
https://www.readbyqxmd.com/read/28192234/meningococcal-carriage-in-dutch-adolescents-and-young-adults-a-cross-sectional-and-longitudinal-cohort-study
#15
Mariëtte B van Ravenhorst, Merijn W Bijlsma, Marlies A van Houten, Veerle M D Struben, Annaliesa S Anderson, Joseph Eiden, Hao Li, Kathrin U Jansen, Hal Jones, Nicholas Kitchin, Louise Pedneault, Elisabeth A M Sanders, Arie van der Ende
OBJECTIVES: Current information on rates and dynamics of meningococcal carriage is essential for public health policy. This study aimed to determine meningococcal carriage prevalence, its risk factors and duration in the Netherlands, where meningococcal C vaccine coverage is >90%. Several methods to identify serogroups of meningococcal carriage isolates among adolescent and young adults were compared. METHODS: Oropharyngeal swabs from 1715 subjects 13-23 years of age were collected in 2013-2014; 300 were prospectively followed over 8 months...
February 10, 2017: Clinical Microbiology and Infection
https://www.readbyqxmd.com/read/28185740/vaccine-adverse-events-in-a-safety-net-healthcare-system-and-a-managed-care-organization
#16
Komal J Narwaney, Kristin Breslin, Colleen A Ross, Jo Ann Shoup, Kris F Wain, Eric S Weintraub, Michael M McNeil, Simon J Hambidge
BACKGROUND: The Institute of Medicine, in a 2013 report, recommended that the Vaccine Safety Datalink (VSD) expand collaborations to include more diversity in the study population. Kaiser Permanente Colorado (KPCO), an established VSD site, partnered with Denver Health (DH), an integrated safety net healthcare system, to demonstrate the feasibility of integrating DH data within the VSD. Prior to incorporating the data, we examined the identification of specific vaccine associated adverse events (VAEs) in these two distinct healthcare systems...
February 6, 2017: Vaccine
https://www.readbyqxmd.com/read/28178106/low-uptake-of-meningococcal-c-vaccination-in-france-a-cross-sectional-nationwide-survey-of-general-practitioners-perceptions-attitudes-and-practices
#17
Marion Le Maréchal, Nelly Agrinier, Lisa Fressard, Pierre Verger, Céline Pulcini
BACKGROUND-: Meningococcal C glycoconjugate vaccine (MenCV) has been recommended in France since 2010, but its uptake remains low (64% coverage among two-year-olds in 2014). Because general practitioners (GPs) are the cornerstone of the French vaccination program, we sought to assess their perceptions, attitudes, practices and recommendations to patients for this vaccine. METHODS-: A cross-sectional survey in 2014 asked a national sample of 1582 GPs if they would recommend MenCV for patients 12 months of age (routine vaccination) and 2-24 years of age (catch-up vaccination), and explored barriers to vaccination...
February 3, 2017: Pediatric Infectious Disease Journal
https://www.readbyqxmd.com/read/28167517/the-need-to-optimize-adolescent-immunization
#18
Henry H Bernstein, Joseph A Bocchini
The adolescent period heralds the pediatric patient's transition into adulthood. It is a time of dynamic development during which effective preventive care measures can promote safe behaviors and the development of lifelong health habits. One of the foundations of preventive adolescent health care is timely vaccination, and every visit can be viewed as an opportunity to update and complete an adolescent's immunizations.In the past decade, the adolescent immunization schedule has expanded to include 2 doses of quadrivalent meningococcal conjugate vaccine, 1 dose of tetanus, diphtheria, acellular pertussis, absorbed vaccine, 2 or 3 doses of human papillomavirus vaccine, depending on the child's age, and an annual influenza vaccine...
March 2017: Pediatrics
https://www.readbyqxmd.com/read/28158417/meningococcal-carriage-evaluation-in-response-to-a-serogroup-b-meningococcal-disease-outbreak-and-mass-vaccination-campaign-at-a-college-rhode-island-2015-2016
#19
Heidi M Soeters, Melissa Whaley, Nicole Alexander-Scott, Koren V Kanadanian, Jessica R MacNeil, Stacey W Martin, Lucy A McNamara, Kenneth Sicard, Cynthia Vanner, Jeni Vuong, Xin Wang, Utpala Bandy, Manisha Patel
No abstract text is available yet for this article.
February 4, 2017: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/28152332/antibody-persistence-up-to-5%C3%A2-y-after-vaccination-with-a-quadrivalent-meningococcal-acwy-tetanus-toxoid-conjugate-vaccine-in-adolescents
#20
Beatriz P Quiambao, Ashish Bavdekar, Anand Prakash Dubey, Hemant Jain, Devayani Kolhe, Véronique Bianco, Jacqueline M Miller, Marie Van der Wielen
Long-term protection against meningococcal disease relies on antibody persistence after vaccination. We report antibody persistence up to 5 y after vaccination in adolescents who received a single dose of either meningococcal serogroups A, C, W, Y tetanus toxoid conjugate vaccine (MenACWY-TT, Pfizer) or MenACWY polysaccharide vaccine (MenPS, GSK Vaccines) at the age of 11-17 y in the randomized controlled primary study NCT00464815. In this phase III, open, controlled, multi-center persistence follow-up study conducted in India and the Philippines (NCT00974363), antibody persistence was evaluated by a serum bactericidal antibody assay using rabbit complement (rSBA) yearly, up to year 5 after vaccination...
February 2, 2017: Human Vaccines & Immunotherapeutics
keyword
keyword
106661
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"